An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists [Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica]

Trial Profile

An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists [Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica]

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Expanded access
  • Most Recent Events

    • 22 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 11 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top